Medigen Vaccine Biologics Corporation (6547.TWO) develops and manufactures vaccines and biopharmaceuticals targeting infectious diseases using cell-based technologies. The company offers ENVACGEN enterovirus A71 vaccine for preventing severe complications in children; MVC-COV1901 COVID-19 protein subunit vaccine authorized for emergency use in Taiwan and Paraguay; Fluvacgen trivalent influenza vaccine; and quadrivalent influenza vaccine in Phase III trials; alongside dengue vaccine post-Phase II, anti-RSV vaccine in Phase I, and pipelines for enterovirus D68 and multivalent Coxsackie enterovirus. It wholesales these products and medical devices primarily in Taiwan, Southeast Asia, and developing markets, with manufacturing in Hsinchu Biomedical Science Park, Zhubei City. Founded in 2012 and headquartered in Zhubei City, Hsinchu County, Taiwan, Medigen Vaccine Biologics operates as a subsidiary of Medigen Biotechnology Corp. In January 2025, the company collaborated with Substipharm Biologics to expand ENVACGEN distribution in Southeast Asia; it filed a new drug application for its enterovirus 71 vaccine in Vietnam in 2023 and partnered with the WHO C-TAP Initiative that year to out-license COVID-19 technology globally.